Not all patients with T-cell prolymphocytic leukemia (T-PLL) present with aggressive, rapidly progressing disease. A subset — estimated at up to 20–30% of patients — demonstrate an initially stable or slowly progressive course, meeting criteria for inactive disease.
This scenario applies to patients who are asymptomatic and have stable or slowly progressive T-PLL, characterised by the absence of disease-related constitutional symptoms, the absence of symptomatic bone marrow failure, no rapidly enlarging lymph nodes, spleen, or liver, no increasing lymphocytosis, and no extranodal involvement.
In this setting, the recommended approach involves a period of observation rather than immediate anti-leukemic intervention. Structured monitoring at regular intervals is the cornerstone of management.
Because there is no evidence that asymptomatic patients with T-PLL with inactive disease ("inactive T-PLL") would benefit from immediate treatment, it should be restricted to patients with active or symptomatic disease ("active T-PLL").
However, up to 20% to 30% of patients with T-PLL demonstrate initially stable or slowly progressive disease.
For inactive T-PLL (indicating an early phase and avoiding the misleading term "indolent"), a period of observation is recommended unless there is disease progression or development of disease-related symptoms (Table 4).
During the observation period, blood counts should be performed at monthly intervals along with a clinical examination.
View source ↗